VA to test whether GLP-1s can treat alcohol use disorder

The Department of Veterans Affairs is launching a clinical trial to see if semaglutide, the chemical used in popular weight loss drugs, can also be used to help treat alcoholism.

The new trial, announced on Thursday, will screen more than 600 veterans with “moderate or severe” alcohol use disorder over the course of 24 weeks, seeing if taking semaglutide-based medications can help reduce alcohol intake.

Enrollment for the Cessation or Reduction of Alcohol Consumption in Veterans trial, or “CRAVE trial,” started this week. The VA is looking for veterans between the ages of 18 and 80 for the study. Participants will receive weekly injections of either semaglutide or a placebo.

Researchers will monitor them for 24 weeks to track “changes in drinking, health, and quality of life to determine whether the medication offers a meaningful new treatment option. The nearly half-year study is expected to wrap up in the spring of 2027. The trial will be carried out at 18 VA medical centers around the country.

Top Stories This Week

• News

  Medal of Honor recipient Dakota Meyer now a special assistant to Hegseth

  By Jeff Schogol
• News

  Pentagon picks Lt. Gen. Kevin Admiral to lead Army Europe and Africa

  By Nicholas Slayton
• News

  Pentagon reveals hundreds of new Iran war casualties

  By Matt White, Patty Nieberg, Nicholas Slayton

Semaglutide was developed as a way to help treat diabetes but has been proven to be effective as a weight loss drug. It is used in drugs on the market such as Ozempic and Wegovy.

A study published in March, cited by the VA in its announcement of the CRAVE trial, found that taking GLP-1 medications showed a reduced risk of developing substance use disorders and risks in people who already experience such disorders.

“This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed…